The companies ADARx Pharmaceuticals, Electra Therapeutics, and Enveda bagged the biggest biotech funding rounds overall in ...

As BIOSPAIN 2026 comes to end, delve into what as been at the center of this edition's discussion: what comes after we have ...

PMOS, formerly PCOS, still has no approved dedicated drug. Discover the new PMOS treatments in development, from GLP-1s to ...

Over the past decade, a succession of new GvHD treatments targeting different components of the immune response have been ...

Brain biomarkers were long hard to pin down. See how new Parkinson's and Alzheimer's biomarkers are changing that.

Learn how to choose and integrate automated liquid handling solutions while overcoming challenges and supporting flexible lab ...

Delve into the AstraZeneca pipeline strategy in 2026 as its oncology franchise keeps growing and it invests in diversification.

Discover biotech and big pharma’s emerging interest in developing macrocyclic drugs for cardiometabolic diseases.

The biotech industry is under legal fire. While 2024 has been a year of resilience in terms of performance for the industry, there’s been a sharp increase in the number of class action lawsuits ...